An experimental HIV prevention pill being developed by Merck could be mass produced for less than $5 per patient a year ...

Merck & Co.’s experimental cholesterol pill slashed levels of the artery-clogging plaque far more than older tablets in the ...

Merck is bulking up its portfolio ahead of its best-selling cancer drug Keytruda losing patent protection in 2028.

By Siddhi Mahatole March 25 (Reuters) - Merck said on Wednesday it would buy biotech firm Terns Pharma for $6.7 billion, as ...

The drugmaker has been seeking to bolster its pipeline as its top-selling drug, Keytruda, is set to lose patent protection.

Merck said on Wednesday it would buy biotech Terns Pharma for US$6.7 billion, as the drugmaker races to bolster ...

March 25 (Reuters) - Merck said on Wednesday it would buy biotech Terns Pharma in a deal valued at up to $6.7 billion, as the ...

Merck & Co., Inc. (NYSE:MRK) is included in our list of the best stocks to buy for financial stability. On March 25, 2026, ...

Check out the latest Gilead Sciences Inc. (GILD) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment.

Adagene said early clinical trial results showed that its experimental cancer drug, muzastotug, worked better at higher doses when combined with Merck's Keytruda.

A new pill, enlicitide, reduced LDL (“bad”) cholesterol by about 60% in a large clinical trial, matching the power of injectable therapies. Because it’s taken orally, it could overcome one of the ...